Related Disease Stocks List

Related ETFs - A few ETFs which own one or more of the above listed Related Disease stocks.

Recent Signals

Date Stock Signal Type
2021-08-02 BFRA 20 DMA Resistance Bearish
2021-08-02 BFRA Narrow Range Bar Range Contraction
2021-08-02 CATB Non-ADX 1,2,3,4 Bearish Bearish Swing Setup
2021-08-02 GLMD 200 DMA Resistance Bearish
2021-08-02 GLMD Volume Surge Other
2021-08-02 GLMD Wide Range Bar Range Expansion
2021-08-02 GLMD MACD Bullish Signal Line Cross Bullish
2021-08-02 GLMD Pocket Pivot Bullish Swing Setup
2021-08-02 GLMD Expansion Pivot Buy Setup Bullish Swing Setup
2021-08-02 GLMD Crossed Above 20 DMA Bullish
2021-08-02 GLMD Crossed Above 50 DMA Bullish
2021-08-02 GLTO 20 DMA Resistance Bearish
2021-08-02 IVA Stochastic Buy Signal Bullish
2021-08-02 IVA Narrow Range Bar Range Contraction
2021-08-02 IVA Non-ADX 1,2,3,4 Bearish Bearish Swing Setup
2021-08-02 NBIX Crossed Above 20 DMA Bullish
2021-08-02 NBIX Stochastic Buy Signal Bullish
2021-08-02 NXTC Stochastic Reached Oversold Weakness
2021-08-02 REGN Bollinger Band Squeeze Range Contraction
2021-08-02 REGN Cup with Handle Other

Related Disease Stocks Recent News

Date Stock Title
Aug 2 NBIX Neurocrine Biosciences Q2 2021 Earnings Preview
Aug 2 IVA Inventiva announces the implementation of an At-The-Market program in the United States
Aug 2 REGN Doctor on COVID-19: 'People who are vaccinated are still very susceptible to infection'
Aug 2 REGN Regeneron: Rapid Growth Seems To Be On A Pause
Aug 2 REGN Will Eylea & Dupixent Drive Regeneron's (REGN) Q2 Earnings?
Aug 2 GLMD Galmed Stock Jumps As FDA Signs Off Use Of Aramchol Meglumine In Late Stage NASH Trial
Aug 2 GLMD Galmed Pharma jumps 8% on FDA green light to use Aramchol Meglumine in late-stage ARMOR study
Aug 2 GLMD FDA Agrees with Galmed's Plan to use Aramchol Meglumine in the Randomized Double-Blind Placebo-Controlled Part of the Phase 3 ARMOR study
Aug 2 REGN FDA Approves Regeneron - Roche's COVID-19 Antibody Cocktail For Post-Exposure Prophylaxis
Aug 1 GLMD The Week Ahead In Biotech (Aug. 1-7): Biopharma Earnings Pick Up Pace, Eton Awaits FDA Decision, Focus On Pending Clinical Readouts and IPOs
Jul 30 REGN Regeneron Pharmaceuticals (REGN) Long-Term Investor Alert: Contact Johnson Fistel Regarding Investigation
Jul 30 REGN Regeneron wins expanded authorization from FDA for COVID-19 antibody cocktail
Jul 30 REGN FDA okays Regeneron COVID-19 antibody as preventive in high-risk settings
Jul 30 REGN Doctor on Delta variant: ’All of us are extremely concerned’
Jul 30 REGN FDA Expands Authorized Use of REGEN-COV™ (casirivimab and imdevimab)
Jul 30 REGN 15 Most Valuable Biotech Companies in the World
Jul 30 REGN Is a Meltdown on the Way for Moderna Stock?
Jul 29 REGN We must move towards vaccine mandates to get ahead of Covid-19: Doctor
Jul 29 GLMD Galmed Pharmaceuticals to Report Second Quarter 2021 Financial Results and Provide Business Update on Thursday August 5
Jul 29 REGN Sanofi Q2 Performance Benefits From Dupixent, Vaccines; Raises 2021 Profit Forecast
Related Industries: Biotechnology